Abstract
Alzheimers disease (AD) is a severe chronic neurodegenerative disease. During aging and neurodegeneration, misfolded proteins accumulate and activate the ubiquitin-proteasome system. The aim of the present study is to explore whether ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, ubiquitin or proteasome activity are affected in peripheral blood mononuclear cells (PBMC) of AD, mild cognitive impairment (MCI) and Parkinsons disease (PD) patients compared to healthy subjects. PBMCs were isolated from EDTA blood samples and extracts were analyzed by Western Blot. Proteasome activity was measured with fluorogenic substrates. When compared to healthy subjects, the concentration of enzyme E1 was increased in PBMCs of AD patients, whereas the concentration of the enzyme E2 was decreased in the same patients. Ubiquitin levels and proteasome activity were unchanged in AD patients. No changes in enzyme expression or proteasome activity was observed in MCI patients compared to healthy and AD subjects. In PD patients E2 levels and proteasomal activity were significantly reduced, while ubiquitin and E1 levels were unchanged. The present investigation demonstrates the differences in enzyme and proteasome activity patterns of AD and PD patients. These results suggest that different mechanisms are involved in regulating the ubiquitin-proteasomal system in different neurodegenerative diseases.
Keywords: PBMC, mild cognitive impairment, diagnosis, blood cells
Current Alzheimer Research
Title: Ubiquitin Enzymes, Ubiquitin and Proteasome Activity in Blood Mononuclear Cells of MCI, Alzheimer and Parkinson Patients
Volume: 7 Issue: 6
Author(s): C. Ullrich, R. Mlekusch, A. Kuschnig, J. Marksteiner and C. Humpel
Affiliation:
Keywords: PBMC, mild cognitive impairment, diagnosis, blood cells
Abstract: Alzheimers disease (AD) is a severe chronic neurodegenerative disease. During aging and neurodegeneration, misfolded proteins accumulate and activate the ubiquitin-proteasome system. The aim of the present study is to explore whether ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, ubiquitin or proteasome activity are affected in peripheral blood mononuclear cells (PBMC) of AD, mild cognitive impairment (MCI) and Parkinsons disease (PD) patients compared to healthy subjects. PBMCs were isolated from EDTA blood samples and extracts were analyzed by Western Blot. Proteasome activity was measured with fluorogenic substrates. When compared to healthy subjects, the concentration of enzyme E1 was increased in PBMCs of AD patients, whereas the concentration of the enzyme E2 was decreased in the same patients. Ubiquitin levels and proteasome activity were unchanged in AD patients. No changes in enzyme expression or proteasome activity was observed in MCI patients compared to healthy and AD subjects. In PD patients E2 levels and proteasomal activity were significantly reduced, while ubiquitin and E1 levels were unchanged. The present investigation demonstrates the differences in enzyme and proteasome activity patterns of AD and PD patients. These results suggest that different mechanisms are involved in regulating the ubiquitin-proteasomal system in different neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Ullrich C., Mlekusch R., Kuschnig A., Marksteiner J. and Humpel C., Ubiquitin Enzymes, Ubiquitin and Proteasome Activity in Blood Mononuclear Cells of MCI, Alzheimer and Parkinson Patients, Current Alzheimer Research 2010; 7 (6) . https://dx.doi.org/10.2174/156720510792231766
DOI https://dx.doi.org/10.2174/156720510792231766 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Current Alzheimer Research Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Endothelial Dysfunction Induced by Cadmium and Mercury and its Relationship to Hypertension
Current Hypertension Reviews Non-Ceruloplasmin Copper as a Stratification Biomarker of Alzheimer’s Disease Patients: How to Measure and Use It
Current Alzheimer Research Mapping Exchangeable Protons to Monitor Protein Alterations in the Brain of an Alzheimer’s Disease Mouse Model by Using MRI
Current Alzheimer Research Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Pin1: A New Genetic Link between Alzheimer’s Disease, Cancer and Aging
Current Aging Science Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Older Adults with Amnestic Mild Cognitive Impairment Exhibit Exacerbated Gait Slowing under Dual-Task Challenges
Current Alzheimer Research Insulin-Degrading Enzyme: A Link Between Alzheimer’s and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry Biochemical Differentiation of Cholinesterases from Normal and Alzheimers Disease Cortex
Current Alzheimer Research MiR-22-3p Regulates Amyloid β Deposit in Mice Model of Alzheimer's Disease by Targeting Mitogen-activated Protein Kinase 14
Current Neurovascular Research To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research The Role of Microbial Agents in the Etiology of Schizophrenia: An Infectious Hypothesis for Psychosis?
Current Immunology Reviews (Discontinued) Estrous Cycle and HIV-1 Tat Protein Influence Cocaine-Conditioned Place Preference and Induced Locomotion of Female Mice
Current HIV Research Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology New Vessel Formation in the Central Nervous System During Tumor Growth, Vascular Malformations, and Moyamoya
Current Neurovascular Research A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer’s Disease
Current Clinical Pharmacology